[1]
Mavissakalian, M.R.; Jones, B.; Olson, S. Absence of placebo response in obsessive-compulsive disorder. J. Nerv. Ment. Dis., 1990, 178(4), 268-270. [http://dx.doi.org/10.1097/00005053-199004000-00010]. [PMID: 2319236].
[2]
Goodman, W.K.; Price, L.H.; Rasmussen, S.A.; Mazure, C.; Fleischmann, R.L.; Hill, C.L.; Heninger, G.R.; Charney, D.S. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch. Gen. Psychiatry, 1989, 46(11), 1006-1011. [http://dx.doi.org/10.1001/archpsyc.1989.01810110048007]. [PMID: 2684084].
[3]
Goodman, W.K.; Price, L.H.; Rasmussen, S.A.; Mazure, C.; Delgado, P.; Heninger, G.R.; Charney, D.S. The yale-brown obsessive compulsive scale. II. Validity. Arch. Gen. Psychiatry, 1989, 46(11), 1012-1016. [http://dx.doi.org/10.1001/archpsyc.1989.01810110054008]. [PMID: 2510699].
[4]
Guy, W. ECDEU Assessment Manual of Psychopharmacology — Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S;, Department of health, education, and welfare, public health service, alcohol, drug abuse, and mental health administration, NIMH psychopharmacology research branch, division of extramural research programs,. 1976, 218-222.
[5]
Walsh, B.T.; Seidman, S.N.; Sysko, R.; Gould, M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA, 2002, 287(14), 1840-1847. [http://dx.doi.org/10.1001/jama.287.14.1840]. [PMID: 11939870].
[6]
Sysko, R.; Walsh, B.T. A systematic review of placebo response in studies of bipolar mania. J. Clin. Psychiatry, 2007, 68(8), 1213-1217. [http://dx.doi.org/10.4088/JCP.v68n0807]. [PMID: 17854245].
[7]
Vieta, E.; Cruz, N. Increasing rates of placebo response over time in mania studies. J. Clin. Psychiatry, 2008, 69(4), 681-682. [http://dx.doi.org/10.4088/JCP.v69n0423g]. [PMID: 18507494].
[8]
Ackerman, D.L.; Greenland, S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J. Clin. Psychopharmacol., 2002, 22(3), 309-317. [http://dx.doi.org/10.1097/00004714-200206000-00012]. [PMID: 12006902].
[9]
Fineberg, N.A.; Hawley, C.J.; Gale, T.M. Are placebo-controlled trials still important for obsessive compulsive disorder? Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(3), 413-422. [http://dx.doi.org/10.1016/j.pnpbp.2005.11.012]. [PMID: 16413647].
[10]
Kirsch, I.; Sapirstein, G. Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. How Expectancies Shape Behavior; Kirsch, I., Ed.; American Psychological Association: Washington, DC, 1999, pp. 303-320. [http://dx.doi.org/10.1037/10332-012]
[11]
Kobak, K.A.; Greist, J.H.; Jefferson, J.W.; Katzelnick, D.J.; Henk, H.J. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology (Berl.), 1998, 136(3), 205-216. [http://dx.doi.org/10.1007/s002130050558]. [PMID: 9566805].
[12]
Montgomery, S.A. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharm. Med., 1980, 1, 189-192.
[13]
Thorén, P.; Åsberg, M.; Cronholm, B.; Jörnestedt, L.; Träskman, L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch. Gen. Psychiatry, 1980, 37(11), 1281-1285. [http://dx.doi.org/10.1001/archpsyc.1980.01780240079009]. [PMID: 7436690].
[14]
Mavissakalian, M.; Turner, S.M.; Michelson, L.; Jacob, R. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II. Am. J. Psychiatry, 1985, 142(5), 572-576. [http://dx.doi.org/10.1176/ajp.142.5.572]. [PMID: 3885761].
[15]
Foa, E.B.; Steketee, G.; Kozak, M.J.; Dugger, D. Effects of imipramine on depression and obsessive-compulsive symptoms. Psychiatry Res., 1987, 21(2), 123-136. [http://dx.doi.org/10.1016/0165-1781(87)90070-9]. [PMID: 3615688].
[16]
Foa, E.B.; Steketee, G.; Kozak, M.J.; Dugger, D. Imipramine and placebo in the treatment of obsessive-compulsives: their effect on depression and on obsessional symptoms. Psychopharmacol. Bull., 1987, 23(1), 8-11. [PMID: 3602334].
[17]
Perse, T.L.; Greist, J.H.; Jefferson, J.W.; Rosenfeld, R.; Dar, R. Fluvoxamine treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 1987, 144(12), 1543-1548. [http://dx.doi.org/10.1176/ajp.144.12.1543]. [PMID: 3120604].
[18]
Goodman, W.K.; Price, L.H.; Rasmussen, S.A.; Delgado, P.L.; Heninger, G.R.; Charney, D.S. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch. Gen. Psychiatry, 1989, 46(1), 36-44. [http://dx.doi.org/10.1001/archpsyc.1989.01810010038006]. [PMID: 2491940].
[19]
Jenike, M.A.; Baer, L.; Summergrad, P.; Minichiello, W.E.; Holland, A.; Seymour, R. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. 1990, 147, 923-928. erratum, Jenike and Baer, 147, 1393.
[20]
Chouinard, G. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int. Clin. Psychopharmacol., 1992, 7(Suppl. 2), 37-41. [http://dx.doi.org/10.1097/00004850-199210002-00007]. [PMID: 1484177].
[21]
Riddle, M.A.; Scahill, L.; King, R.A.; Hardin, M.T.; Anderson, G.M.; Ort, S.I.; Smith, J.C.; Leckman, J.F.; Cohen, D.J. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry, 1992, 31(6), 1062-1069. [http://dx.doi.org/10.1097/00004583-199211000-00011]. [PMID: 1429406].
[22]
Montgomery, S.A.; McIntyre, A.; Osterheider, M.; Sarteschi, P.; Zitterl, W.; Zohar, J.; Birkett, M.; Wood, A.J. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur. Neuropsychopharmacol., 1993, 3(2), 143-152. [http://dx.doi.org/10.1016/0924-977X(93)90266-O]. [PMID: 8364350].
[23]
Tollefson, G.D.; Rampey, A.H., Jr; Potvin, J.H.; Jenike, M.A.; Rush, A.J.; Dominguez, R.A.; Koran, L.M.; Shear, M.K.; Goodman, W.; Genduso, L.A. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder Arch. Gen. Psychiatry, 1994, 51, 559-567. erratum 51, 864
[24]
Tollefson, G.D.; Birkett, M.; Koran, L.; Genduso, L. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J. Clin. Psychiatry, 1994, 55(Suppl.), 69-76. [PMID: 7961535].
[25]
Turner, S.M.; Jacob, R.G.; Beidel, D.C.; Himmelhoch, J. Fluoxetine treatment of obsessive-compulsive disorder. J. Clin. Psychopharmacol., 1985, 5(4), 207-212. [http://dx.doi.org/10.1097/00004714-198508000-00003]. [PMID: 3894437].
[26]
Pfeffer, C.R.; Klerman, G.L.; Hurt, S.W.; Lesser, M.; Peskin, J.R.; Siefker, C.A. Suicidal children grow up: demographic and clinical risk factors for adolescent suicide attempts. J. Am. Acad. Child Adolesc. Psychiatry, 1991, 30(4), 609-616. [http://dx.doi.org/10.1097/00004583-199107000-00013]. [PMID: 1890095].
[27]
Flament, M.F.; Rapoport, J.L.; Berg, C.J.; Sceery, W.; Kilts, C.; Mellström, B.; Linnoila, M. Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch. Gen. Psychiatry, 1985, 42(10), 977-983. [http://dx.doi.org/10.1001/archpsyc.1985.01790330057007]. [PMID: 3899048].
[28]
Pato, M.T.; Zohar-Kadouch, R.; Zohar, J.; Murphy, D.L. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am. J. Psychiatry, 1988, 145(12), 1521-1525. [http://dx.doi.org/10.1176/ajp.145.12.1521]. [PMID: 3057923].
[29]
Jenike, M.A.; Baer, L.; Summergrad, P.; Weilburg, J.B.; Holland, A.; Seymour, R. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. Am. J. Psychiatry, 1989, 146(10), 1328-1330. [http://dx.doi.org/10.1176/ajp.146.10.1328]. [PMID: 2675643].
[30]
Greist, J.H.; Jefferson, J.W.; Rosenfeld, R.; Gutzmann, L.D.; March, J.S.; Barklage, N.E. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients. J. Clin. Psychiatry, 1990, 51(7), 292-297. [PMID: 2195006].
[31]
Jenike, M.A.; Hyman, S.; Baer, L.; Holland, A.; Minichiello, W.E.; Buttolph, L.; Summergrad, P.; Seymour, R.; Ricciardi, J. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am. J. Psychiatry, 1990, 147(9), 1209-1215. [http://dx.doi.org/10.1176/ajp.147.9.1209]. [PMID: 2143637].
[32]
Katz, R.J.; DeVeaugh-Geiss, J.; Landau, P. Clomipramine in obsessive-compulsive disorder. Biol. Psychiatry, 1990, 28(5), 401-414. [http://dx.doi.org/10.1016/0006-3223(90)90408-T]. [PMID: 2207219].
[33]
Mavissakalian, M.R.; Jones, B.; Olson, S.; Perel, J.M. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J. Clin. Psychopharmacol., 1990, 10(4), 261-268. [http://dx.doi.org/10.1097/00004714-199008000-00005]. [PMID: 2286699].
[34]
Montgomery, S.A.; Montgomery, D.B.; Fineberg, N. Early response with clomipramine in obsessive compulsive disorder--a placebo controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1990, 14(5), 719-727. [http://dx.doi.org/10.1016/0278-5846(90)90042-F]. [PMID: 2293252].
[35]
McDougle, C.J.; Price, L.H.; Goodman, W.K.; Charney, D.S.; Heninger, G.R. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J. Clin. Psychopharmacol., 1991, 11(3), 175-184. [http://dx.doi.org/10.1097/00004714-199106000-00005]. [PMID: 1820757].
[36]
Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1991, 48(8), 730-738. [http://dx.doi.org/10.1001/archpsyc.1991.01810320054008]. [PMID: 1883256].
[37]
DeVeaugh-Geiss, J.; Moroz, G.; Biederman, J.; Cantwell, D.; Fontaine, R.; Greist, J.H.; Reichler, R.; Katz, R.; Landau, P. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial. J. Am. Acad. Child Adolesc. Psychiatry, 1992, 31(1), 45-49. [http://dx.doi.org/10.1097/00004583-199201000-00008]. [PMID: 1537780].
[38]
Mallya, G.K.; White, K.; Waternaux, C.; Quay, S. Short- and long-term treatment with obsessive-compulsive disorder with fluvoxamine. Ann. Clin. Psychiatry, 1992, 4, 77-80. [http://dx.doi.org/10.3109/10401239209150443].
[39]
Pigott, T.A.; L’Heureux, F.; Rubenstein, C.S.; Bernstein, S.E.; Hill, J.L.; Murphy, D.L. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J. Clin. Psychopharmacol., 1992, 12(3), 156-162. [http://dx.doi.org/10.1097/00004714-199206000-00002]. [PMID: 1629380].
[40]
Stein, D.J.; Hollander, E.; Mullen, L.S. Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive compulsive disorder. Hum. Psychopharmacol., 1992, 7, 389-395. [http://dx.doi.org/10.1002/hup.470070604].
[41]
Grady, T.A.; Pigott, T.A.; L’Heureux, F.; Hill, J.L.; Bernstein, S.E.; Murphy, D.L. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am. J. Psychiatry, 1993, 150(5), 819-821. [http://dx.doi.org/10.1176/ajp.150.5.819]. [PMID: 8480832].
[42]
Hoehn-Saric, R.; McLeod, D.R.; Zimmerli, W.D.; Hipsley, P.A. Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine. J. Clin. Psychiatry, 1993, 54(7), 272-276. [PMID: 8335655].
[43]
McDougle, C.J.; Goodman, W.K.; Leckman, J.F.; Holzer, J.C.; Barr, L.C.; McCance-Katz, E.; Heninger, G.R.; Price, L.H. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am. J. Psychiatry, 1993, 150(4), 647-649. [http://dx.doi.org/10.1176/ajp.150.4.647]. [PMID: 8465885].
[44]
McDougle, C.J.; Goodman, W.K.; Leckman, J.F.; Lee, N.C.; Heninger, G.R.; Price, L.H. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch. Gen. Psychiatry, 1994, 51(4), 302-308. [http://dx.doi.org/10.1001/archpsyc.1994.03950040046006]. [PMID: 8161290].
[45]
Greist, J.; Chouinard, G.; DuBoff, E.; Halaris, A.; Kim, S.W.; Koran, L.; Liebowitz, M.; Lydiard, R.B.; Rasmussen, S.; White, K.; Sikes, C. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1995, 52(4), 289-295. [http://dx.doi.org/10.1001/archpsyc.1995.03950160039008]. [PMID: 7702445].
[46]
Fux, M.; Levine, J.; Aviv, A.; Belmaker, R.H. Inositol treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 1996, 153(9), 1219-1221. [http://dx.doi.org/10.1176/ajp.153.9.1219]. [PMID: 8780431].
[47]
Goodman, W.K.; Kozak, M.J.; Liebowitz, M.; White, K.L. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int. Clin. Psychopharmacol., 1996, 11(1), 21-29. [http://dx.doi.org/10.1097/00004850-199603000-00003]. [PMID: 8732310].
[48]
Nakajima, T.; Kudo, Y.; Yamashita, I.; Asai, M.; Kamijima, K.; Murasaki, M.; Yamaguchi, N.; Saito, M.; Yamawaki, S.; Nishizono, M.; Hishikawa, Y.; Machiyama, Y.; Yamauchi, T.; Moriya, N.; Toru, M.; Hirose, T.; Kojima, T.; Shimizu, M.; Tamura, A.; Endo, S.; Suzuki, J.; Takemasa, K.; Uno, M.; Hasegawa, K.; Kariya, T. Clinical usefulness of Fluvoxamine Maleate (SME3110), a selective serotonin reuptake inhibitor, in the treatment of obsessive compulsive disorder: A double blind, placebo-controlled study investigating the therapeutic dose range and the efficacy of SME3110. J. Clin. Therap. Med., 1996, 12(3), 409-437. [Rinshou Iyaku].
[49]
Zohar, J.; Judge, R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br. J. Psychiatry, 1996, 169(4), 468-474. [http://dx.doi.org/10.1192/bjp.169.4.468]. [PMID: 8894198].
[50]
Jenike, M.A.; Baer, L.; Minichiello, W.E.; Rauch, S.L.; Buttolph, M.L. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am. J. Psychiatry, 1997, 154(9), 1261-1264. [http://dx.doi.org/10.1176/ajp.154.9.1261]. [PMID: 9286186].
[51]
Lindsay, M.; Crino, R.; Andrews, G. Controlled trial of exposure and response prevention in obsessive-compulsive disorder. Br. J. Psychiatry, 1997, 171, 135-139. [http://dx.doi.org/10.1192/bjp.171.2.135]. [PMID: 9337948].
[52]
Ushijima, S.; Kamijima, K.; Asai, M.; Murasaki, M.; Nakajima, T.; Kudo, Y.; Tashiro, N.; Kurihara, M.; Miura, S. Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor in the treatment of obsessive- compulsive disorder: A double blind placebo controlled trial. Jpn. J. Neuropsychopharmacol., (Nihon Shinkei Seishin Yakurigaku Zasshi or Nihon Shinkei Seishin Yakuri Gakkai),, 1997, 19(6), 603-623.
[53]
Fallon, B.A.; Liebowitz, M.R.; Campeas, R.; Schneier, F.R.; Marshall, R.; Davies, S.; Goetz, D.; Klein, D.F. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch. Gen. Psychiatry, 1998, 55(10), 918-924. [http://dx.doi.org/10.1001/archpsyc.55.10.918]. [PMID: 9783563].
[54]
Li, J.; Xiang, H.; Du, H. Clinical controlled study of paroxetine and clomipramine in treatment of obsessive- compulsive disorder. Zhonghua jing shen ke za zhi (Chinese Journal of Psychiatry), 1998, 31, 215-217 (李建勋,向虎,杜海英. 帕罗西汀与氯丙咪嗪治疗强迫症的临床对照研究. 中华精神科杂志. 编辑部邮箱 1998年 04期31, 215-217. (1998, (4), 23-25)). (erroneously referred to as: Jianxun L, Hu X, Haiying D. Clinical controlled study of paroxetine and clomipramine in treatment of obsessive- compulsive disorder. Chinese J. Psychiatry, 1998, 31, 215-217. [Chinese].
[55]
March, J.S.; Biederman, J.; Wolkow, R.; Safferman, A.; Mardekian, J.; Cook, E.H.; Cutler, N.R.; Dominguez, R.; Ferguson, J.; Muller, B.; Riesenberg, R.; Rosenthal, M.; Sallee, F.R.; Wagner, K.D.; Steiner, H. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial J.A.M.A, , 1998, 280, 1752-1756. erratum 283, 1293
[56]
Kronig, M.H.; Apter, J.; Asnis, G.; Bystritsky, A.; Curtis, G.; Ferguson, J.; Landbloom, R.; Munjack, D.; Riesenberg, R.; Robinson, D.; Roy-Byrne, P.; Phillips, K.; Du Pont, I.J. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J. Clin. Psychopharmacol., 1999, 19(2), 172-176. [http://dx.doi.org/10.1097/00004714-199904000-00013]. [PMID: 10211919].
[57]
Dannon, P.N.; Sasson, Y.; Hirschmann, S.; Iancu, I.; Grunhaus, L.J.; Zohar, J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur. Neuropsychopharmacol., 2000, 10(3), 165-169. [http://dx.doi.org/10.1016/S0924-977X(00)00065-1]. [PMID: 10793318].
[58]
McDougle, C.J.; Epperson, C.N.; Pelton, G.H.; Wasylink, S.; Price, L.H. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry, 2000, 57(8), 794-801. [http://dx.doi.org/10.1001/archpsyc.57.8.794]. [PMID: 10920469].
[59]
Geller, D.A.; Hoog, S.L.; Heiligenstein, J.H.; Ricardi, R.K.; Tamura, R.; Kluszynski, S.; Jacobson, J.G. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J. Am. Acad. Child Adolesc. Psychiatry, 2001, 40(7), 773-779. [http://dx.doi.org/10.1097/00004583-200107000-00011]. [PMID: 11437015].
[60]
Montgomery, S.A.; Kasper, S.; Stein, D.J.; Bang, H.K.; Lemming, O.M. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 2001, 16(2), 75-86. [http://dx.doi.org/10.1097/00004850-200103000-00002]. [PMID: 11236072].
[61]
Riddle, M.A.; Reeve, E.A.; Yaryura-Tobias, J.A.; Yang, H.M.; Claghorn, J.L.; Gaffney, G.; Greist, J.H.; Holland, D.; McConville, B.J.; Pigott, T.; Walkup, J.T. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J. Am. Acad. Child Adolesc. Psychiatry, 2001, 40(2), 222-229. [http://dx.doi.org/10.1097/00004583-200102000-00017]. [PMID: 11211371].
[62]
Romano, S.; Goodman, W.; Tamura, R.; Gonzales, J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J. Clin. Psychopharmacol., 2001, 21(1), 46-52. [http://dx.doi.org/10.1097/00004714-200102000-00009]. [PMID: 11199947].
[63]
Atmaca, M.; Kuloglu, M.; Tezcan, E.; Gecici, O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int. Clin. Psychopharmacol., 2002, 17(3), 115-119. [http://dx.doi.org/10.1097/00004850-200205000-00004]. [PMID: 11981352].
[64]
Greist, J.H.; Marks, I.M.; Baer, L.; Kobak, K.A.; Wenzel, K.W.; Hirsch, M.J.; Mantle, J.M.; Clary, C.M. Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. J. Clin. Psychiatry, 2002, 63(2), 138-145. [http://dx.doi.org/10.4088/JCP.v63n0209]. [PMID: 11874215].
[65]
Koran, L.M.; Hackett, E.; Rubin, A.; Wolkow, R.; Robinson, D. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 2002, 159(1), 88-95. [http://dx.doi.org/10.1176/appi.ajp.159.1.88]. [PMID: 11772695].
[66]
Liebowitz, M.R.; Turner, S.M.; Piacentini, J.; Beidel, D.C.; Clarvit, S.R.; Davies, S.O.; Graae, F.; Jaffer, M.; Lin, S.H.; Sallee, F.R.; Schmidt, A.B.; Simpson, H.B. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J. Am. Acad. Child Adolesc. Psychiatry, 2002, 41(12), 1431-1438. [http://dx.doi.org/10.1097/00004583-200212000-00014]. [PMID: 12447029].
[67]
Geller, D.A.; Biederman, J.; Stewart, S.E.; Mullin, B.; Farrell, C.; Wagner, K.D.; Emslie, G.; Carpenter, D. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? J. Child Adolesc. Psychopharmacol., 2003, 13(Suppl. 1), S19-S29. [http://dx.doi.org/10.1089/104454603322126313]. [PMID: 12880497].
[68]
Hollander, E.; Kaplan, A.; Stahl, S.M. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J. Biol. Psychiatry, 2003, 4(1), 30-34. [http://dx.doi.org/10.3109/15622970309167908]. [PMID: 12582975].
[69]
Hollander, E.; Baldini Rossi, N.; Sood, E.; Pallanti, S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol., 2003, 6(4), 397-401. [http://dx.doi.org/10.1017/S1461145703003730]. [PMID: 14604454].
[70]
Hollander, E.; Allen, A.; Steiner, M.; Wheadon, D.E.; Oakes, R.; Burnham, D.B. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J. Clin. Psychiatry, 2003, 64(9), 1113-1121. [http://dx.doi.org/10.4088/JCP.v64n0919]. [PMID: 14628989].
[71]
Hollander, E.; Koran, L.M.; Goodman, W.K.; Greist, J.H.; Ninan, P.T.; Yang, H.; Li, D.; Barbato, L.M. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J. Clin. Psychiatry, 2003, 64(6), 640-647. [http://dx.doi.org/10.4088/JCP.v64n0604]. [PMID: 12823077].
[72]
Bystritsky, A.; Ackerman, D.L.; Rosen, R.M.; Vapnik, T.; Gorbis, E.; Maidment, K.M.; Saxena, S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J. Clin. Psychiatry, 2004, 65(4), 565-568. [http://dx.doi.org/10.4088/JCP.v65n0418]. [PMID: 15119922].
[73]
Denys, D.; de Geus, F.; van Megen, H.J.; Westenberg, H.G. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J. Clin. Psychiatry, 2004, 65(8), 1040-1048. [http://dx.doi.org/10.4088/JCP.v65n0803]. [PMID: 15323587].
[74]
Fux, M.; Benjamin, J.; Nemets, B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J. Psychiatr. Res., 2004, 38(3), 323-325. [http://dx.doi.org/10.1016/S0022-3956(03)00077-3]. [PMID: 15003438].
[75]
Geller, D.A.; Wagner, K.D.; Emslie, G.; Murphy, T.; Carpenter, D.J.; Wetherhold, E.; Perera, P.; Machin, A.; Gardiner, C. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J. Am. Acad. Child Adolesc. Psychiatry, 2004, 43(11), 1387-1396. [http://dx.doi.org/10.1097/01.chi.0000138356.29099.f1]. [PMID: 15502598].
[76]
Kamijima, K.; Murasaki, M.; Asai, M.; Higuchi, T.; Nakajima, T.; Taga, C.; Matsunaga, H. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin. Neurosci., 2004, 58(4), 427-433. [http://dx.doi.org/10.1111/j.1440-1819.2004.01278.x]. [PMID: 15298657].
[77]
Shapira, N.A.; Ward, H.E.; Mandoki, M.; Murphy, T.K.; Yang, M.C.; Blier, P.; Goodman, W.K. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol. Psychiatry, 2004, 55(5), 553-555. [http://dx.doi.org/10.1016/j.biopsych.2003.11.010]. [PMID: 15023585].
[78]
Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA, 2004, 292(16), 1969-1976. [http://dx.doi.org/10.1001/jama.292.16.1969]. [PMID: 15507582].
[79]
Carey, P.D.; Vythilingum, B.; Seedat, S.; Muller, J.E.; van Ameringen, M.; Stein, D.J. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. [ISRCTN83050762] BMC Psychiatry, 2005, 5, 5. . [http://dx.doi.org/10.1186/1471-244X-5-5]. [PMID: 15667657].
[80]
Erzegovesi, S.; Guglielmo, E.; Siliprandi, F.; Bellodi, L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur. Neuropsychopharmacol., 2005, 15(1), 69-74. [http://dx.doi.org/10.1016/j.euroneuro.2004.04.004]. [PMID: 15572275].
[81]
Fineberg, N.A.; Sivakumaran, T.; Roberts, A.; Gale, T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int. Clin. Psychopharmacol., 2005, 20(4), 223-226. [http://dx.doi.org/10.1097/00004850-200507000-00005]. [PMID: 15933483].
[82]
Foa, E.B.; Liebowitz, M.R.; Kozak, M.J.; Davies, S.; Campeas, R.; Franklin, M.E.; Huppert, J.D.; Kjernisted, K.; Rowan, V.; Schmidt, A.B.; Simpson, H.B.; Tu, X. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 2005, 162(1), 151-161. [http://dx.doi.org/10.1176/appi.ajp.162.1.151]. [PMID: 15625214].
[83]
Kobak, K.A.; Taylor, L.V.; Bystritsky, A.; Kohlenberg, C.J.; Greist, J.H.; Tucker, P.; Warner, G.; Futterer, R.; Vapnik, T. St John’s wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int. Clin. Psychopharmacol., 2005, 20(6), 299-304. [http://dx.doi.org/10.1097/00004850-200511000-00003]. [PMID: 16192837].
[84]
Koran, L.M.; Aboujaoude, E.; Bullock, K.D.; Franz, B.; Gamel, N.; Elliott, M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry, 2005, 66(3), 353-359. [http://dx.doi.org/10.4088/JCP.v66n0312]. [PMID: 15766302].
[85]
Li, X.; May, R.S.; Tolbert, L.C.; Jackson, W.T.; Flournoy, J.M.; Baxter, L.R. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J. Clin. Psychiatry, 2005, 66(6), 736-743. [http://dx.doi.org/10.4088/JCP.v66n0610]. [PMID: 15960567].
[86]
Nakatani, E.; Nakagawa, A.; Nakao, T.; Yoshizato, C.; Nabeyama, M.; Kudo, A.; Isomura, K.; Kato, N.; Yoshioka, K.; Kawamoto, M. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine. Psychother. Psychosom., 2005, 74(5), 269-276. [http://dx.doi.org/10.1159/000086317]. [PMID: 16088264].
[87]
Buchsbaum, M.S.; Hollander, E.; Pallanti, S.; Baldini Rossi, N.; Platholi, J.; Newmark, R.; Bloom, R.; Sood, E. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology, 2006, 53(3), 157-168. [http://dx.doi.org/10.1159/000093342]. [PMID: 16707915].
[88]
O’Connor, K.P.; Aardema, F.; Robillard, S.; Guay, S.; Pélissier, M.C.; Todorov, C.; Borgeat, F.; Leblanc, V.; Grenier, S.; Doucet, P. Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder. Acta Psychiatr. Scand., 2006, 113(5), 408-419. [http://dx.doi.org/10.1111/j.1600-0447.2006.00767.x]. [PMID: 16603032].
[89]
Fineberg, N.A.; Tonnoir, B.; Lemming, O.; Stein, D.J. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur. Neuropsychopharmacol., 2007, 17(6-7), 430-439. [http://dx.doi.org/10.1016/j.euroneuro.2006.11.005]. [PMID: 17240120].
[90]
Stein, D.J.; Andersen, E.W.; Tonnoir, B.; Fineberg, N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr. Med. Res. Opin., 2007, 23(4), 701-711. [http://dx.doi.org/10.1185/030079907X178838]. [PMID: 17407626].
[91]
Amiaz, R.; Fostick, L.; Gershon, A.; Zohar, J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur. Neuropsychopharmacol., 2008, 18(6), 455-461. [http://dx.doi.org/10.1016/j.euroneuro.2008.01.006]. [PMID: 18353618].
[92]
Kordon, A.; Wahl, K.; Koch, N.; Zurowski, B.; Anlauf, M.; Vielhaber, K.; Kahl, K.G.; Broocks, A.; Voderholzer, U.; Hohagen, F. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J. Clin. Psychopharmacol., 2008, 28(5), 550-554. [http://dx.doi.org/10.1097/JCP.0b013e318185e735]. [PMID: 18794652].
[93]
Greenberg, W.M.; Benedict, M.M.; Doerfer, J.; Perrin, M.; Panek, L.; Cleveland, W.L.; Javitt, D.C. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J. Psychiatr. Res., 2009, 43(6), 664-670. [http://dx.doi.org/10.1016/j.jpsychires.2008.10.007]. [PMID: 19046587].
[94]
Sayyah, M.; Boostani, H.; Pakseresht, S.; Malaieri, A. Efficacy of aqueous extract of Echium amoenum in treatment of obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33(8), 1513-1516. [http://dx.doi.org/10.1016/j.pnpbp.2009.08.021]. [PMID: 19737592].
[95]
Mowla, A.; Khajeian, A.M.; Sahraian, A.; Chohedri, A.H.; Kashkoli, F. Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial. CNS Spectr., 2010, 15(11), 613-617. [http://dx.doi.org/10.1017/S1092852912000065]. [PMID: 24726048].
[96]
Storch, E.A.; Murphy, T.K.; Goodman, W.K.; Geffken, G.R.; Lewin, A.B.; Henin, A.; Micco, J.A.; Sprich, S.; Wilhelm, S.; Bengtson, M.; Geller, D.A. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol. Psychiatry, 2010, 68(11), 1073-1076. [http://dx.doi.org/10.1016/j.biopsych.2010.07.015]. [PMID: 20817153].
[97]
Sayyah, M.; Boostani, H.; Pakseresht, S.; Malayeri, A. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res., 2011, 189(3), 403-406. [http://dx.doi.org/10.1016/j.psychres.2011.01.019]. [PMID: 21329988].
[98]
Muscatello, M.R.; Bruno, A.; Pandolfo, G.; Micò, U.; Scimeca, G.; Romeo, V.M.; Santoro, V.; Settineri, S.; Spina, E.; Zoccali, R.A. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J. Clin. Psychopharmacol., 2011, 31(2), 174-179. [http://dx.doi.org/10.1097/JCP.0b013e31820e3db6]. [PMID: 21346614].
[99]
Berlin, H.A.; Koran, L.M.; Jenike, M.A.; Shapira, N.A.; Chaplin, W.; Pallanti, S.; Hollander, E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry, 2011, 72(5), 716-721. [http://dx.doi.org/10.4088/JCP.09m05266gre]. [PMID: 20816027].
[100]
Pakseresht, S.; Boostani, H.; Sayyah, M. Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study. J. Complement. Integr. Med., 2011, 8(1), 32. [http://dx.doi.org/10.2202/1553-3840.1465]. [PMID: 22718671].
[101]
Sayyah, M.; Olapour, A.; Saeedabad, Ys.; Yazdan, P.R.; Malayeri, A. Evaluation of oral zinc sulfate effect on obsessive-compulsive disorder: a randomized placebo-controlled clinical trial. Nutrition, 2012, 28(9), 892-895. [http://dx.doi.org/10.1016/j.nut.2011.11.027]. [PMID: 22465904].
[102]
Sayyah, M.; Sayyah, M.; Boostani, H.; Ghaffari, S.M.; Hoseini, A. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress. Anxiety, 2012, 29(10), 850-854. [http://dx.doi.org/10.1002/da.21996]. [PMID: 22933237].
[103]
Afshar, H.; Roohafza, H.; Mohammad-Beigi, H.; Haghighi, M.; Jahangard, L.; Shokouh, P.; Sadeghi, M.; Hafezian, H. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol., 2012, 32(6), 797-803. [http://dx.doi.org/10.1097/JCP.0b013e318272677d]. [PMID: 23131885].
[104]
Bruno, A.; Micò, U.; Pandolfo, G.; Mallamace, D.; Abenavoli, E.; Di Nardo, F.; D’Arrigo, C.; Spina, E.; Zoccali, R.A.; Muscatello, M.R. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J. Psychopharmacol. (Oxford), 2012, 26(11), 1456-1462. [http://dx.doi.org/10.1177/0269881111431751]. [PMID: 22351381].
[105]
Askari, N.; Moin, M.; Sanati, M.; Tajdini, M.; Hosseini, S.M.; Modabbernia, A.; Najand, B.; Salimi, S.; Tabrizi, M.; Ashrafi, M.; Hajiaghaee, R.; Akhondzadeh, S. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs, 2012, 26(10), 883-892. [http://dx.doi.org/10.2165/11635850-000000000-00000]. [PMID: 22873680].
[106]
Ghaleiha, A.; Entezari, N.; Modabbernia, A.; Najand, B.; Askari, N.; Tabrizi, M.; Ashrafi, M.; Hajiaghaee, R.; Akhondzadeh, S. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J. Psychiatr. Res., 2013, 47(2), 175-180. [http://dx.doi.org/10.1016/j.jpsychires.2012.09.015]. [PMID: 23063327].
[107]
Storch, E.A.; Bussing, R.; Small, B.J.; Geffken, G.R.; McNamara, J.P.; Rahman, O.; Lewin, A.B.; Garvan, C.S.; Goodman, W.K.; Murphy, T.K. Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder. Behav. Res. Ther., 2013, 51(12), 823-829. [http://dx.doi.org/10.1016/j.brat.2013.09.007]. [PMID: 24184429].
[108]
Haghighi, M.; Jahangard, L.; Mohammad-Beigi, H.; Bajoghli, H.; Hafezian, H.; Rahimi, A.; Afshar, H.; Holsboer-Trachsler, E.; Brand, S. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl.), 2013, 228(4), 633-640. [http://dx.doi.org/10.1007/s00213-013-3067-z]. [PMID: 23525525].
[109]
Storch, E.A.; Goddard, A.W.; Grant, J.E.; De Nadai, A.S.; Goodman, W.K.; Mutch, P.J.; Medlock, C.; Odlaug, B.; McDougle, C.J.; Murphy, T.K. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J. Clin. Psychiatry, 2013, 74(6), e527-e532. [http://dx.doi.org/10.4088/JCP.12m08278]. [PMID: 23842022].
[110]
Rodriguez, C.I.; Kegeles, L.S.; Levinson, A.; Feng, T.; Marcus, S.M.; Vermes, D.; Flood, P.; Simpson, H.B. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology, 2013, 38(12), 2475-2483. [http://dx.doi.org/10.1038/npp.2013.150]. [PMID: 23783065].
[111]
Simpson, H.B.; Foa, E.B.; Liebowitz, M.R.; Huppert, J.D.; Cahill, S.; Maher, M.J.; McLean, C.P.; Bender, J., Jr; Marcus, S.M.; Williams, M.T.; Weaver, J.; Vermes, D.; Van Meter, P.E.; Rodriguez, C.I.; Powers, M.; Pinto, A.; Imms, P.; Hahn, C.G.; Campeas, R. Cognitive-behavioral therapy vs. risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry, 2013, 70(11), 1190-1199. [http://dx.doi.org/10.1001/jamapsychiatry.2013.1932]. [PMID: 24026523].
[112]
Park, J.M.; Small, B.J.; Geller, D.A.; Murphy, T.K.; Lewin, A.B.; Storch, E.A. Does D-cycloserine augmentation of CBT improve therapeutic homework compliance for pediatric obsessive-compulsive disorder? J. Child Fam. Stud., 2014, 23(5), 863-871. [http://dx.doi.org/10.1007/s10826-013-9742-1]. [PMID: 24999301].
[113]
Grant, P.J.; Joseph, L.A.; Farmer, C.A.; Luckenbaugh, D.A.; Lougee, L.C.; Zarate, C.A., Jr; Swedo, S.E. 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology, 2014, 39(6), 1453-1459. [http://dx.doi.org/10.1038/npp.2013.343]. [PMID: 24356715].
[114]
Mataix-Cols, D.; Turner, C.; Monzani, B.; Isomura, K.; Murphy, C.; Krebs, G.; Heyman, I. Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial. Br. J. Psychiatry, 2014, 204(1), 77-78. [http://dx.doi.org/10.1192/bjp.bp.113.126284]. [PMID: 24262813].
[115]
Afshar, H.; Akuchekian, S.; Mahaky, B.; Zarean, E. Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. J. Res. Med. Sci., 2014, 19(10), 976-981. [PMID: 25538783].
[116]
Sarris, J.; Oliver, G.; Camfield, D.A.; Dean, O.M.; Dowling, N.; Smith, D.J.; Murphy, J.; Menon, R.; Berk, M.; Blair-West, S.; Ng, C.H. N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study. CNS Drugs, 2015, 29(9), 801-809. [http://dx.doi.org/10.1007/s40263-015-0272-9]. [PMID: 26374743].
[117]
Pittenger, C.; Bloch, M.H.; Wasylink, S.; Billingslea, E.; Simpson, R.; Jakubovski, E.; Kelmendi, B.; Sanacora, G.; Coric, V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J. Clin. Psychiatry, 2015, 76(8), 1075-1084. [http://dx.doi.org/10.4088/JCP.14m09123]. [PMID: 26214725].
[118]
Jahanbakhsh, S.P.; Manteghi, A.A.; Emami, S.A.; Mahyari, S.; Gholampour, B.; Mohammadpour, A.H.; Sahebkar, A. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial. Complement. Ther. Med., 2016, 27, 25-29. [http://dx.doi.org/10.1016/j.ctim.2016.03.018]. [PMID: 27515872].
[119]
Paydary, K.; Akamaloo, A.; Ahmadipour, A.; Pishgar, F.; Emamzadehfard, S.; Akhondzadeh, S. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J. Clin. Pharm. Ther., 2016, 41(2), 214-219. [http://dx.doi.org/10.1111/jcpt.12370]. [PMID: 26931055].
[120]
Khalkhali, M.; Aram, S.; Zarrabi, H.; Kafie, M.; Heidarzadeh, A. Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. Iran. J. Psychiatry, 2016, 11(2), 104-114. [PMID: 27437007].
[121]
Rutrick, D.; Stein, D.J.; Subramanian, G.; Smith, B.; Fava, M.; Hasler, G.; Cha, J.H.; Gasparini, F.; Donchev, T.; Ocwieja, M.; Johns, D.; Gomez-Mancilla, B. Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: a proof-of-concept, randomized, placebo-controlled, phase 2 study. Adv. Ther., 2017, 34(2), 524-541. [http://dx.doi.org/10.1007/s12325-016-0468-5]. [PMID: 28044255].
[122]
Feng, B.; Zhang, Z.J.; Zhu, R.M.; Yuan, G.Z.; Luo, L.Y.; McAlonan, G.M.; Xu, F.Z.; Chen, J.; Liu, L.Y.; Lv, Y.Y.; Wong, H.K.; Zhang, Y.; Zhu, L.X. Transcutaneous electrical acupoint stimulation as an adjunct therapy for obsessive-compulsive disorder: A randomized controlled study. J. Psychiatr. Res., 2016, 80, 30-37. [http://dx.doi.org/10.1016/j.jpsychires.2016.05.015]. [PMID: 27281260].
[123]
de Leeuw, A.S.; van Megen, H.J.; Kahn, R.S.; Westenberg, H.G. d-cycloserine addition to exposure sessions in the treatment of patients with obsessive-compulsive disorder. Eur. Psychiatry, 2017, 40, 38-44. [http://dx.doi.org/10.1016/j.eurpsy.2016.06.011]. [PMID: 27837671].
[124]
Asnaani, A.; Kaczkurkin, A.N.; Alpert, E.; McLean, C.P.; Simpson, H.B.; Foa, E.B. The effect of treatment on quality of life and functioning in OCD. Compr. Psychiatry, 2017, 73, 7-14. [http://dx.doi.org/10.1016/j.comppsych.2016.10.004]. [PMID: 27838572].
[125]
Ahmadpanah, M.; Reihani, A.; Ghaleiha, A.; Soltanian, A.; Haghighi, M.; Jahangard, L.; Sadeghi Bahmani, D.; Holsboer-Trachsler, E.; Brand, S. Buprenorphine augmentation improved symptoms of OCD, compared to placebo - Results from a randomized, double-blind and placebo-controlled clinical trial. J. Psychiatr. Res., 2017, 94, 23-28. [http://dx.doi.org/10.1016/j.jpsychires.2017.06.004]. [PMID: 28647677].
[126]
Modarresi, A.; Sayyah, M.; Razooghi, S.; Eslami, K.; Javadi, M.; Kouti, L. Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial. Pharmacopsychiatry, 2017, 2018 51(6), 263-269. [http://dx.doi.org/10.1055/s-0043-120268] [PMID: 29100251]
[127]
Costa, D.L.C.; Diniz, J.B.; Requena, G.; Joaquim, M.A.; Pittenger, C.; Bloch, M.H.; Miguel, E.C.; Shavitt, R.G. Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry, 2017, 78(7), e766-e773. [http://dx.doi.org/10.4088/JCP.16m11101]. [PMID: 28617566].
[128]
Arabzadeh, S.; Shahhossenie, M.; Mesgarpour, B.; Rezaei, F.; Shalbafan, M.R.; Ghiasi, Z.; Akhondzadeh, S. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. Hum. Psychopharmacol., 2017, 32(4) [http://dx.doi.org/10.1002/hup.2584]. [PMID: 28485008].
[129]
Alphs, L.; Benedetti, F.; Fleischhacker, W.W.; Kane, J.M. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int. J. Neuropsychopharmacol., 2012, 15(7), 1003-1014. [http://dx.doi.org/10.1017/S1461145711001738]. [PMID: 22217384].
[130]
Khan, A.; Fahl, M.K.; Faucett, J.; Khan, S.S.; Brown, W.A. Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013. World Psychiatry, 2017, 16(2), 181-192. [http://dx.doi.org/10.1002/wps.20421]. [PMID: 28498591].
[131]
Khan, A.; Fahl, M.K.; Schilling, J.; Brown, W.A. Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of data from the Food and Drug Administration 1990-2016. PLoS One, 2018, 13(2)e0193043 [http://dx.doi.org/10.1371/journal.pone.0193043]. [PMID: 29489874].
[132]
Rutherford, B.R.; Pott, E.; Tandler, J.M.; Wall, M.M.; Roose, S.P.; Lieberman, J.A. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry, 2014, 71(12), 1409-1421. [http://dx.doi.org/10.1001/jamapsychiatry.2014.1319]. [PMID: 25321611].
[133]
Sugarman, M.A.; Kirsch, I.; Huppert, J.D. Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis. J. Affect. Disord., 2017, 218, 217-226. [http://dx.doi.org/10.1016/j.jad.2017.04.068]. [PMID: 28477500].
[134]
Kasper, S.; Dold, M. Factors contributing to the increasing placebo response in antidepressant trials. World Psychiatry, 2015, 14(3), 304-306. [http://dx.doi.org/10.1002/wps.20245]. [PMID: 26407782].
[135]
Khin, N.A.; Chen, Y.F.; Yang, Y.; Yang, P.; Laughren, T.P. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J. Clin. Psychiatry, 2012, 73(6), 856-864. [http://dx.doi.org/10.4088/JCP.11r07539]. [PMID: 22687813].
[136]
Tuttle, A.H.; Tohyama, S.; Ramsay, T.; Kimmelman, J.; Schweinhardt, P.; Bennett, G.J.; Mogil, J.S. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain, 2015, 156(12), 2616-2626. [http://dx.doi.org/10.1097/j.pain.0000000000000333]. [PMID: 26307858].
[137]
Mancini, M.; Wade, A.G.; Perugi, G.; Lenox-Smith, A.; Schacht, A. Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants. J. Psychiatr. Res., 2014, 51, 21-29. [http://dx.doi.org/10.1016/j.jpsychires.2014.01.001]. [PMID: 24462042].
[138]
Perugi, G.; Akiskal, H.S.; Gemignani, A.; Pfanner, C.; Presta, S.; Milanfranchi, A.; Lensi, P.; Ravagli, S.; Maremmani, I.; Cassano, G.B. Episodic course in obsessive-compulsive disorder. Eur. Arch. Psychiatry Clin. Neurosci., 1998, 248(5), 240-244. [http://dx.doi.org/10.1007/s004060050044]. [PMID: 9840370].
[139]
Lin, H.; Yeh, C.B.; Peterson, B.S.; Scahill, L.; Grantz, H.; Findley, D.B.; Katsovich, L.; Otka, J.; Lombroso, P.J.; King, R.A.; Leckman, J.F. Assessment of symptom exacerbations in a longitudinal study of children with Tourette’s syndrome or obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry, 2002, 41(9), 1070-1077. [http://dx.doi.org/10.1097/00004583-200209000-00007]. [PMID: 12218428].
[140]
Hróbjartsson, A.; Gøtzsche, P.C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N. Engl. J. Med., 2001, 344(21), 1594-1602. [http://dx.doi.org/10.1056/NEJM200105243442106]. [PMID: 11372012].
[141]
Busch, A.B.; He, Y.; Zelevinsky, K.; O’Malley, A.J. Predicting Participation in Psychiatric Randomized Controlled Trials: Insights From the STEP-BD. Psychiatr. Serv., 2015, 66(8), 817-823. [http://dx.doi.org/10.1176/appi.ps.201300557]. [PMID: 25828873].
[142]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th; (DSM-5®); Arlington, VA: American Psychiatric Publishing, Inc, 2013.
[143]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, ; 4th; –Text Revision, (DSM-IV-TR™) Washington, DC: American Psychiatric Association, 2000.
[144]
Fountoulakis, K.N.; McIntyre, R.S.; Carvalho, A.F. From randomized controlled trials of antidepressant drugs to the meta-analytic synthesis of evidence: methodological aspects lead to discrepant findings. Curr. Neuropharmacol., 2015, 13(5), 605-615. [http://dx.doi.org/10.2174/1570159X13666150630174343]. [PMID: 26467410].
[145]
Kaptchuk, T.J.; Stason, W.B.; Davis, R.B.; Legedza, A.R.; Schnyer, R.N.; Kerr, C.E.; Stone, D.A.; Nam, B.H.; Kirsch, I.; Goldman, R.H. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ, 2006, 332(7538), 391-397. [http://dx.doi.org/10.1136/bmj.38726.603310.55]. [PMID: 16452103].
[146]
Wartolowska, K.; Judge, A.; Hopewell, S.; Collins, G.S.; Dean, B.J.; Rombach, I.; Brindley, D.; Savulescu, J.; Beard, D.J.; Carr, A.J. Use of placebo controls in the evaluation of surgery: systematic review. BMJ, 2014, 348, g3253. [http://dx.doi.org/10.1136/bmj.g3253]. [PMID: 24850821].
[147]
Kaptchuk, T.J.; Goldman, P.; Stone, D.A.; Stason, W.B. Do medical devices have enhanced placebo effects? J. Clin. Epidemiol., 2000, 53(8), 786-792. [http://dx.doi.org/10.1016/S0895-4356(00)00206-7]. [PMID: 10942860].
[148]
Brunoni, A.R.; Lopes, M.; Kaptchuk, T.J.; Fregni, F. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One, 2009, 4(3)e4824 [http://dx.doi.org/10.1371/journal.pone.0004824]. [PMID: 19293925].
